MyVisionTest News Archive

Displaying news items tagged with UK (More tags »)
SELECT PAGE
First <<  1 2   >> Last

National Health Service
Mar 27, 2011
In draft guidance issued this month, the National Institute for Health and Clinical Excellence (NICE) in Britian has not recommended Lucentis (ranibizumab) for treating diabetic macular oedema (DMO). This draft guidance has been issued for consultation. NICE has not yet issued final guidance to the NHS. People with diabetes frequently...

Full Article


National Health Service
Feb 27, 2011
The North East Treatment Advisory Group (NETAG) has produced an appraisal of bevacizumab (Avastin) and ranibizumab (Lucentis), in the management of macular oedema secondary to retinal vein occlusion and recommended that bevacizumab 1.25 mg using a 'when required' (PRN) regimen is recommended for use within NHS North East as this regimen is...

Full Article


National Health Service
Jan 21, 2011
The NHS in the United Kingdom has moved a step closer to approving Avastin to for the treatment of age-related macular degeneration (AMD), in spite of attempts by drug companies to block it. The National Institute for Health and Clinical Excellence (Nice), which decides which drugs may be prescribed on the NHS, has decided to move towards an...

Full Article

Tags: Avastin, UK, NICE, NHS

Low vision aids
Jan 16, 2011
A new study finds that low vision device training does not improve self-reported difficulty with activities of daily living. Participants were recruited from those attending their first low vision assessment (LVA). Participants completed the Mass of Activity Inventory (MAI) questionnaire by telephone before their appointment. After LVA,...

Full Article


National Health Service
Oct 19, 2009
The Berkshire Priorities Committee, which advises the National Health Service (NHS) of the United Kingdom (UK) on health care interventions and policies, has issued a "Low Priority" funding directive for anti-VEGF therapy for ocular neovascularization from conditions other than age-related macular degeneration (AMD), including ocular...

Full Article


Reading
Oct 16, 2009
Reading performance improved after eccentric viewing training according to a new study. Central visual loss caused by conditions such as age related macular degeneration (AMD) is the most common cause of blindness in most developed countries. Eccentric viewing training aims to teach patients how to utilise those non-central (eccentric) parts of...

Full Article


Loneliness
Sep 25, 2009
The emotional trauma of being diagnosed with sight loss is potentially devastating. Yet, while there is clear evidence of a need for emotional support, there is very little information on how best to provide it, according to a new study. "Not enough attention has been given to the emotional impact of sight loss," says Dr. Angela McCullagh,...

Full Article


Diabetes
Jul 25, 2009
In the EUREYE study, a positive association between diabetes mellitus and neovascular age-related macular degeneration (AMD) was found. Other than age, the epidemiologic risk factors most consistently associated with AMD are cardiovascular risk factors. Many cardiovascular disease risk factors have been suggested as potential risk factors for...

Full Article


Radio
Jun 20, 2009
A move from analogue to digital audio broadcasting (DAB) radio may leave people with sight problems left out of Britain's digital revolution if steps are not taken to assist in the switchover, as laid out in the communications Minister Lord Carter's Digital Britain report. DAB is a digital radio technology for broadcasting radio stations,...

Full Article


Laboratory glassware
Apr 19, 2009
British scientists have developed the world's first stem cell therapy for age-related macular degeneration (AMD). Surgeons predict it will become a routine, one-hour procedure that will be generally available in six or seven years' time. The treatment involves replacing a layer of degenerated retinal cells with new ones created from embryonic...

Full Article


SELECT PAGE
First <<  1 2   >> Last
Most Popular
Less - past - More